Although hypophosphatemia has been implicated as a cause of respiratory failure, its impact on respiratory muscle function in patients hospitalized for other reasons remains to be determined. Maximal inspiratory pressures (MIP) and maximal expiratory pressures (MEP) were measured at the bedside in 23 hospitalized patients with serum phosphate levels less than 2.5 mg/dl, and these measurements were repeated daily during phosphate repletion until serum phosphate levels reached the normal range. A control group consisted of 11 normophosphatemic inpatients. Sixteen of 23 hypophosphatemic patients, but none of the control patients (p <O.OOl), exhibited respiratory muscle weakness, defined as a MIP less than 40 cm Hz0 or a MEP less than 70 cm H20. The mean initial MIP and MEP values were also significantly lower for the hypophosphatemic group. A significant correlation existed between initial phosphate level and initial MIP value (r = 0.50, p <0.02). With phosphate repletion, mean f SD MIP increased from -37 f 26 cm Hz0 to -49 f 24 cm Hz0 (p <0.003) and MEP from 60 f 20 cm Hz0 to 69 f 19 cm HP0 (p <0.02). It is concluded that respiratory muscle weakness is common among hypophosphatemic patients and improves with phosphate repletion.
Hypophosphatemia has been implicated as a cause of reversible acute respiratory failure [l-3] and has recently been shown to impair the contractile properties of the diaphragm [4] . Unfortunately, information about hypophosphatemia-associated respiratory muscle weakness is limited to patients in respiratory failure [l-4] . The significance of an incidental finding of hypophosphatemia in patients without respiratory failure has not been examined. We undertook the current study to prospectively evaluate the incidence of respiratory muscle weakness in hospitalized hypophosphatemic patients using bedside measurements of respiratory muscle strength. In addition, we wished to determine if respiratory muscle weakness improves with phosphate repletion.
PA-DENTS AND METHODS
From the Division of Pulmonary and Critical Care Medicine, University of Michigan and Veterans Administration Medical Centers, Ann Arbor, Michigan. Requests for reprints should be addressed to Dr. Marc Peters-Golden, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical Center, 3916 Taubman Center, Ann Arbor, Michigan 48109. Manuscript submitted June 29, 1987 , and accepted in revised form March IO, 1988. Patients. Patients were recruited from the general medical and surgical services of the Ann Arbor Veterans Administration Medical Center during a 30-day study period. Patients were selected for study on the basis of serum phosphate levels as identified from daily clinical chemistry records. The normal range of serum phosphate levels in our laboratory is 2.5 to 4.5 mg/ dl. All patients with a serum phosphate level of less than 2.5 mg/dl were eligible for the hypophosphatemic study group. Patients with a normal serum phosphate level were eligible for the normophosphatemic control group. Patients with known neuromuscular disease or who were within one week of major surgery were excluded from the study. Discretion was used for the inclusion of critically ill patients and patients with cardiac disease, altered mental status, or psychiatric illness that could limit their ability to adequately perform the necessary pulmonary function tests. Informed consent was obtained from all subjects and this study was approved by the Committee on Human Studies of the Ann Arbor Veterans Administration Medical Center. Fifty-four inpatients with hypophosphatemia were identified in the 30-day period during which the study was performed. After application of the just described exclusion criteria, 24 eligible patients consented to participate. One hypophosphatemic patient was subsequently excluded from the study because after one week of phosphate supplementation he had not achieved a normal serum phosphate level. On each of the first and last five days of the study period, two inpatients with normal serum phosphate levels were randomly selected from the clinical chemistry records for eligibility in the control group. After the exclusion criteria described earlier were applied, 11 normophosphatemic patients consented to participate, and these patients comprised the control group. Protocol.
Upon entry into the study, the patients' baseline respiratory muscle strength was assessed using maximal inspiratory pressures (MIP) and maximal expiratory pressures (MEP). Pressure measurements were determined from a dial manometer (R.F.M.D. Gauge, #395946, OEM Medical Inc., Richmond, Virginia) connected to a plastic cylinder that was fitted on the proximal end with a rubber mouthpiece similar to that described by Black and Hyatt [5] . The dial manometer records a maximum negative pressure reading of -80 cm Hz0 and a maximum positive pressure reading of 80 cm H20. Values exceeding the dial maxima were recorded as -80 or 80 cm H20, respectively. Measurements were made while the patients were sitting and wearing a noseclip. MIP was measured at the end of a tidal expiration and MEP was measured at near total lung capacity. The pressures measured were maintained for at least one second and the best of three efforts was recorded. Reproducibility of these determinations was within IO percent for all patients. Forced vital capacity (FVC) and forced expiratory volume in one second (FEV,) were measured using a portable digital spirometer (Eagle One, W.E. Collins Co., Braintree, Massachusetts).
The best of three trials was recorded.
Hypophosphatemic patients were given supplemental phosphorus in the form of Neutra-Phos capsules,, two capsules three times a day, until their serum phosphate level reached the normal range. Serum phosphate levels and MIP, MEP, FVC, and FEV, measurements were determined daily until a normal serum phosphate level was obtained. Control patients were not given Neutra-Phos capsules, but had daily measurements of serum phosphate, MIP, MEP, FVC, and FEV, for three days to assess the variability of these parameters and the possibility of a training effect as a cause of improvement in measured pulmonary function. Patients were defined as "weak" if they had a MIP less than 40 cm Hz0 or a MEP less than 70 cm H20. These criteria were arbitrarily defined relative to published normal values in healthy adult men [5-71. Hospital charts were reviewed to identify factors predisposing to hypophosphatemia (intravenous dextrose infusion, total parenteral nutrition, antacid therapy, respiratory alkalosis, and diabetic ketoacidosis, among others) and to determine concomitant electrolyte or metabolic abnormalities. In addition, because of the known ability of theophylline [8] , systemic beta-adrenergics [9] , and digitalis [lo] to increase diaphragmatic contractility, use of these drugs was recorded. Statistical Analysis.
Chi-square analysis was used to assess the significance of differences between prevalences in the two groups. Initial serum phosphate, MIP, MEP, FVC, and FEV, measurements were compared between hypophosphatemic and control patients using the upaired Student t-test. The correlation between MIP measurements and serum phosphate levels was assessed with linear regression. Measurements of serum phosphate, respiratory muscle strength, and ventilatory function were compared preand post-phosphate repletion with the paired Student t-test. The same measurements were compared in control patients at the beginning and end of their three-day trial. A p value of <0.05 was considered significant. All data are expressed as mean f SD.
RESULTS
During the study period, 1,939 serum phosphate determinations were processed by the laboratory, 137 (7.1 percent) of which were less than 2.5 mg/dl. These 137 values originated from 92 patients, 54 of them inpatients. There were 1,145 inpatients at the Ann Arbor Veterans Administration Medical Center during the study period for a 4.7 percent overall prevalence of hypophosphatemia among inpatients. Table I shows the ages, duration of hospitalization at entry, and the major active diagnoses during the study period for all patients studied. There were no significant differences in age or the duration of hospitalization prior to study entry in the two groups. There were two women in the hypophosphatemic group and none in the normophosphatemic group. Two of the hypophosphatemic patients required mechanical ventilation, one for chronic obstructive pulmonary disease with respiratory failure and the second for gastrointestinal bleeding. There were no other significant metabolic abnormalities or any abnormalities in serum potassium, sodium, calcium, or magnesium levels found in any patient during the study period. A predisposing risk factor for hypophosphatemia could be identified in 20 of 23 hypophosphatemic patients and in eight of 11 normophosphatemic patients. The two most common factors found among all patients were antacid therapy (20 patients) and intravenous dextrose infusion (11 patients). The mean initial serum phosphate level for the hypophosphatemic patients was 1.9 f 0.4 mg/dl as compared with a value of 3.6 f 0.5 mg/dl (p <O.OOOOl) for the normophosphatemic control patients. By the criteria utilized, respiratory muscle weakness was found in 16 of 23 hypophosphatemic patients and none of the 11 control patients (p <O.OOl). The mean initial MIP value of the hypophosphatemic patients was significantly lower (p <0.03) than that of the normophosphatemic control patients (-37 f 26 cm HP0 versus -57 f 16 cm H20, respectively) ( Figure 1) . In similar fashion, the mean initial MEP value of the hypophosphatemic patients was significantly lower (p <0.006) than that of the control patients (60 f 20 cm Hz0 versus 78 f 6 cm H20, respectively) ( Figure 2 ). There was no significant difference in mean FVC or FEV, measurements between the hypophosphatemic patients and the control patients (FVC: 2.47 f 1.1 liters versus 2.89 f 1.01 liters, respectively, and FEV,: 1.76 f 0.83 liters versus 2.34 f 0.91 liters, respectively). Arterial blood gases were obtained for routine clinical indications in eight of the hypophosphatemic patients; the highest partial carbon dioxide pressure recorded was 42 mm Hg. There appeared to be a relationship between the degree of hypophosphatemia and the degree of respiratory muscle weakness when initial MIP measurements were plotted as a function of initial serum phosphate concentration (r = 0.50, p <0.02) (Figure 3) . Of the 12 patients with phosphate levels less than or equal to 2.0 mg/dl, nine demonstrated respiratory muscle weakness by our criteria. The four patients with serum phosphate levels below 1.5 mg/dl all had MIP values below or equal to 20 cm H20. When all serum phosphate and MIP values recorded in both groups during the entire study period were considered, a weaker but still significant correlation between phosphate and MIP persisted (r = 0.28, n = 106, p <0.02).
With phosphate repletion, the mean serum phosphate level increased in the hypophosphatemic patients from 1.9 f 0.4 mg/dl to 3.5 f 0.8 mg/dl (p <O.OOOOl). Hypophosphatemic patients were repleted in 2.0 f 1.3 days. The mean initial serum phosphate level of the control patients was 3.6 f 0.5 mg/dl and was 3.6 f 0.6 mg/dl on the third day of the study. With phosphate repletion, the mean MIP value in the hypophosphatemic patient group increased from -37 f 26 cm H20 to -49 f 24 cm Hz0 (p <0.003). For the normophosphatemic patient group, the mean initial MIP value was -57 f 16 cm HP0 and was -55 f 15 cm Hz0 after three days of testing (p = NS). In similar fashion, there was a significant increase in the mean MEP measurement in the hypophosphatemic patients that was not seen in the normophosphatemic control patients (60 f 20 cm Hz0 to 69 f 19 cm H20, p <0.02, and 78 f 6 cm Hz0 to 77 f 7 cm H20, p = NS, respectively). There were no significant differences in the FVC and FEV, measurements pre-and post-phosphate repletion in the hypophosphatemic patients (FVC: 2.47 f 1.11 liters versus 2.50 f 1.02 liters respectively, and FEV,: 1.76 f 0.83 liters versus 1.8 1 f 0.86 liters, respectively). Similarly, there were no changes in FVC and FEV, after three days of testing in the normophosphatemic control patients (FVC: 2.89 f 1.01 liters versus 2.77 f 0.89 liters, respectively, and FEV,: 2.34 f 0.91 liters versus 2.15 f 0.84 liters, respectively). No patients in either group received beta-adrenergic agents. One hypophosphatemic patient and two normophosphatemic patients were receiving digitalis at entry. Theophylline was used by four hypophosphatemic and two normophosphatemic patients at entry and continued during the study period in all of them. In only one hypophosphatemic patient was theophylline therapy instituted during the study period (Patient 1).
There was no significant difference between the mean MIP value of the hypophosphatemic patients after phosphate repletion (-49 f 24 cm H20) and that obtained after three days of testing in the normophosphatemic control patients (-55 f 15 cm H*O). There was also no significant difference between the mean MEP value in the hypophosphatemic patients following repletion (69 f 19 cm H20) and that in the normophosphatemic patients on Day 3 (77 f 7 cm H*O).
COMMENTS
Our study corroborates previous estimates of the frequency of hypophosphatemia in an adult inpatient population, and for the first time documents an increased incidence of respiratory muscle weakness in these patients using simple measurements at the bedside. Furthermore, we have demonstrated that with phosphate repletion, respiratory muscle strength improves to the level found in normophosphatemic control patients.
Previous studies have shown that hypophosphatemia is not an uncommon finding in an adult inpatient population and our prevalence figure of 4.7 percent if similar to that reported by others [ 11, 12] . It should be noted that because serum phosphate determinations may not have been performed on every inpatient, our prevalence figure represents an approximation. The prevalence of hypophosphatemia increases in those patients receiving antacids or intravenous dextrose, in patients with diabetic ketoacidosis, in patients withdrawing from alcohol; and in patients with a respiratory illness [ 1 l-131. Similar predisposing factors were seen in this study. normophosphatemic control patients. There also appeared to be a relationship between the degree of hypophosphatemia and the degree of respiratory muscle weakness at entry as illustrated by Figure 3 , and throughout the study, when MIP measurements were plotted as a function of phosphate concentration. The weakest patients had the lowest serum phosphate levels. With phosphate repletion, mean MIP and MEP values were no longer significantly different from normophosphatemic control values.
MIP and MEP measurements were selected as indicators of respiratory muscle strength because of their sensitivity and simplicity [7, 14] . Our study has confirmed the fact that spirometric measurements, in contrast, are relatively insensitive indicators of respiratory muscle weakness [ 141. The manometer used in this study was designed to accurately show small changes in positive or negative pressure, but had the inherent limitation of a maximum pressure reading of + or -80 cm H20. As shown in Figures 1 and 2 , this underestimated the true values in several patients in both groups. This limitation, however, tended to bias the data against demonstrating improvement in MIP and MEP values after phosphate repletion in the hypophosphatemic patients: three hypophosphatemic patients increased their MIP from a value below -80 cm Hz0 to a value greater than -80 cm Hz0 as compared with one normophosphatemic patient after three days of testing. Seven hypophosphatemic patients increased their MEP from a value less than 80 cm HP0 to a value greater than 80 cm Hz0 as compared to one normophosphatemic patient. Using a manometer with the same sensitivity and a greater range would change the mean values, for MIP and MEP reported herein and would be expected to show a greater increase in respiratory muscle strength with phosphate repletion.
Although we did not specifically match hypophosphatemic and normophosphatemic patients for severity of illness, selection on the basis of phosphate levels from daily clinical chemistry records should have minimized any bias in favor of noncomparability between the two groups. Indeed, the major diagnoses listed in Table I suggest comparable severities of illness between them. Moreover, as patients were not necessarily entered into the study on admission to the hospital (mean duration of hospitalization upon entry greater than one week for both groups), it is unlikely that the hypophosphatemic patients were more acutely ill at entry. Finally, patients who were uncooperative and unable to perform the tests were excluded, and the high level of reproducibility in MIP and MEP values recorded strongly suggests that patients in the two groups were cooperative to a similar degree.
We chose to measure MIP at near functional residual capacity rather than at residual volume because this is the lung volume at which tidal breathing occurs [7] . There is only one prior report of normal values for MIP at functional residual capacity where measurements ranged from -40 cm Hz0 to greater than -180 cm Hz0 with a mean of -78.8 cm Hz0 [6] . We therefore chose to define weakness conservatively as a MIP less than -40 cm H20. There is some variability in the reported normal range for MEP values in healthy adult men, with a suggested lower limit of normal of approximately 100 cm Hz0 [5, 7, 15] . We arbitrarily chose a value of 70 cm Hz0 or less to define weakness. Using these criteria, we found 16 of 23 hypophosphatemic patients to evidence measurable respiratory muscle weakness as compared with zero of 11 For a number of reasons, we believe that respiratory muscle weakness was a function of hypophosphatemia, and that improvement was due to phosphate repletion: (1) As just indicated, we do not believe that the apparent respiratory muscle weakness in the hypophosphatemic patients can be explained merely by the fact that they were sicker and less able to cooperate. (2) A significant correlation existed between initial phosphate levels and initial MIP values. (3) No other electrolyte or metabolic abnormalities existed that might explain the weakness observed. (4) Although hypercapnia has been reported to impair diaphragmatic function [ 161, none of the eight hypophosphatemic patients on whom arterial blood gas measurements were available exhibited hypercapnia. (5) Improvement in MIP and MEP values with phosphorus repletion occurred within 48 hours in most of the hypophosphatemic patients, too rapid to be accounted for by changes in overall nutritional status. (6) There were no significant changes in spirometric values pre-and postrepletion, effectively excluding changes in obstructive airways disease or resolving acute bronchopulmonary disease as the cause for the improvement in respiratory muscle strength. (7) In only one hypophosphatemic patient was treatment with a drug known to increase diaphragmatic contractility (theophylline) initiated during the study period. This, along with the fact that the hypophosphatemic patients exhibited improvements in MEP (reflecting predominantly skeletal muscle function) as well as MIP (reflecting predominantly diaphragmatic function), rule out the possibility that the observed improvements were attributable to drug therapy. (8) Finally, serial testing in normophosphatemic patients revealed no "training effect" that might itself account for the improvement in MIP and MEP values observed in the hypophosphatemic patients.
Although our results unequivocally demonstrate respiratory muscle weakness in the hypophosphatemic patients as compared with the normophosphatemic patients, marked variability in MIP and MEP values was observed in the former. This most likely reflects the multiple determinants of respiratory muscle function, including not only phosphate level, but also serum potassium [ 171 and magnesium levels [ 181, acid-base status [ 16,191, nutritional status [20] , oxygen delivery to the respiratory muscles [2 1,221, and length-tension relationships of the muscles [21, 22] . Given that serum phosphate is only one of many factors that influence respiratory muscle function, it is not surprising that the correlation between phosphate level and MIP in our study was stronger when only initial (lower) phosphate values, rather than all values, were considered. The mechanism responsible for respiratory muscle weakness in hypophosphatemia is thought to be the diminution in the supply of high-energy phosphate compounds necessary for muscle contraction, and/or a reduction in the supply of 2,3-diphosphoglycerate leading to tissue hypoxia [23, 24] . Although other factors must be corrected when identified, hypophosphatemia is easily reversible if recognized and treated appropriately.
The importance of recognizing hypophosphatemia-associated respiratory muscle weakness is obvious in the patient with acute respiratory failure who cannot be weaned from mechanical ventilation. Recognizing occult respiratory muscle weakness has several important implications. Early recognition of hypophosphatemia-associated respiratory muscle weakness may allow repletion and improvement in respiratory muscle function before acute respiratory failure develops. Our hypophosphatemic patients as a group demonstrated severe respiratory muscle weakness with a mean MIP of -37 cm H20. To place this value in perspective, a recent edition of one major pulmonary textbook lists a MIP value less than -25 cm HP0 as one criterion for instituting mechanical ventilation [25] . In addition, MEP, which was significantly impaired in the hypophosphatemic group, is an important determinant of an effective cough. An impaired cough may result in retained secretions, which may increase the patient's susceptibility to a nosocomial respiratory infection.
Although hypophosphatemia has been implicated as the cause of acute respiratory failure in case reports, the prevalence of occult respiratory muscle weakness in hypophosphatemic patients without acute respiratory failure has not previously been evaluated in a prospective manner. We have demonstrated that respiratory muscle weakness is a common occurrence in hospitalized patients with incidentally detected hypophosphatemia and that the degree of respiratory muscle weakness can be severe. With phosphate repletion, respiratory muscle weakness improves.
